TaiGen Biopharmaceuticals Holdings (4157.TWO) Earnings Analysis

TaiGen Biopharmaceuticals Holdings (4157.TWO) next reports earnings on 2026-08-26, consensus EPS -0.13 TWD. Last quarter (2026-05-11) it beat with EPS -0.0201 TWD vs -0.08 TWD est (+74.9%). It has beaten estimates in 1/1 recent quarters (100%). Trailing P/E 106.13.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 4157.TWO next report earnings?

Next earnings date2026-08-26
Consensus EPS estimate-0.13 TWD
Revenue estimate0.00B

4157.TWO earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-11-0.0201 TWD-0.08 TWD+74.9%Beat
2025-03-13-0.03436 TWDn/an/an/a
2024-08-290.09 TWDn/an/an/a

Beat rate: 1/1 (100%) over reported quarters with consensus data.

4157.TWO valuation and analyst view

Trailing P/E106.13
Trailing EPS0.07517 TWD
Price / book5.76
Dividend yield0.00%
Market cap6.14B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is TaiGen Biopharmaceuticals Holdings (4157.TWO)'s next earnings date?

TaiGen Biopharmaceuticals Holdings is next scheduled to report on 2026-08-26, with a consensus EPS estimate of -0.13 TWD and revenue estimate of 0.00B.

Did 4157.TWO beat earnings last quarter?

In its 2026-05-11 report, 4157.TWO posted EPS of -0.0201 TWD versus a -0.08 TWD estimate — a beat of 74.9%.

What is 4157.TWO's earnings track record?

Over the last 1 reported quarters with consensus data, 4157.TWO beat estimates 1 times (100%).

What is 4157.TWO's current P/E ratio and EPS?

4157.TWO trades at a trailing P/E of 106.13 on trailing EPS of 0.07516780597723627 TWD.

What do analysts rate 4157.TWO?

4157.TWO has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.